Bleeding Disorders Treatment Market is growing significantly due to increasing diagnosis rates and treatment advancements

From GlobeNewswire: 2025-03-04 10:10:00

The Bleeding Disorders Treatment Market was valued at USD 16.35 billion in 2023 and is projected to reach USD 35.17 billion by 2032, with a CAGR of 8.91%. Increasing prevalence of bleeding disorders and advancements in treatment options are driving market growth. Major players include Biogen, Pfizer, Novo Nordisk, and Roche.

Hemophilia A accounted for 55% of total revenue in 2023, driven by rising diagnosis rates and advanced treatment options like recombinant factor VIII concentrates. Recombinant Coagulation Factor Concentrates held a 40% market share in 2023 due to improved safety and efficacy. Hospitals accounted for 50% of total revenue in 2023, offering specialized care and treatment options.

North America dominated the market in 2023, contributing 40% of total revenue. The Asia-Pacific region is expected to grow rapidly due to improving healthcare infrastructure and government initiatives. Recent developments include Pfizer announcing a next-generation recombinant factor VIII concentrate with an extended half-life in January 2024.

Overall, the Bleeding Disorders Treatment Market is witnessing significant growth, with increasing diagnosis rates, advanced treatment options, and supportive government policies driving expansion. Major players are focused on developing innovative therapies to improve patient outcomes and convenience. Roctavian, a gene therapy for severe Hemophilia A, has received EMA approval, a major milestone in the market. The Bleeding Disorders Treatment Market Analysis & Outlook Report 2024-2032 provides insights on market dynamics, statistics, and trends. SNS Insider offers comprehensive market research and consulting services globally to help clients make informed decisions. Access the full report for detailed information.



Read more at GlobeNewswire: Bleeding Disorders Treatment Market Size to Hit USD 35.17